IBDEI022 ; ; 06-AUG-2015
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,415,0)
 ;;=D56.3^^2^20^18
 ;;^UTILITY(U,$J,358.3,415,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,415,1,3,0)
 ;;=3^Thalassemia minor
 ;;^UTILITY(U,$J,358.3,415,1,4,0)
 ;;=4^D56.3
 ;;^UTILITY(U,$J,358.3,415,2)
 ;;=^340497
 ;;^UTILITY(U,$J,358.3,416,0)
 ;;=D56.5^^2^20^7
 ;;^UTILITY(U,$J,358.3,416,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,416,1,3,0)
 ;;=3^Hemoglobin E-beta thalassemia
 ;;^UTILITY(U,$J,358.3,416,1,4,0)
 ;;=4^D56.5
 ;;^UTILITY(U,$J,358.3,416,2)
 ;;=^340498
 ;;^UTILITY(U,$J,358.3,417,0)
 ;;=D56.8^^2^20^19
 ;;^UTILITY(U,$J,358.3,417,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,417,1,3,0)
 ;;=3^Thalassemias NEC
 ;;^UTILITY(U,$J,358.3,417,1,4,0)
 ;;=4^D56.8
 ;;^UTILITY(U,$J,358.3,417,2)
 ;;=^5002305
 ;;^UTILITY(U,$J,358.3,418,0)
 ;;=D57.3^^2^20^16
 ;;^UTILITY(U,$J,358.3,418,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,418,1,3,0)
 ;;=3^Sickle-cell trait
 ;;^UTILITY(U,$J,358.3,418,1,4,0)
 ;;=4^D57.3
 ;;^UTILITY(U,$J,358.3,418,2)
 ;;=^5002313
 ;;^UTILITY(U,$J,358.3,419,0)
 ;;=D57.1^^2^20^13
 ;;^UTILITY(U,$J,358.3,419,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,419,1,3,0)
 ;;=3^Sickle-cell disease without crisis
 ;;^UTILITY(U,$J,358.3,419,1,4,0)
 ;;=4^D57.1
 ;;^UTILITY(U,$J,358.3,419,2)
 ;;=^5002309
 ;;^UTILITY(U,$J,358.3,420,0)
 ;;=D57.02^^2^20^6
 ;;^UTILITY(U,$J,358.3,420,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,420,1,3,0)
 ;;=3^Hb-SS disease with splenic sequestration
 ;;^UTILITY(U,$J,358.3,420,1,4,0)
 ;;=4^D57.02
 ;;^UTILITY(U,$J,358.3,420,2)
 ;;=^5002308
 ;;^UTILITY(U,$J,358.3,421,0)
 ;;=D57.01^^2^20^4
 ;;^UTILITY(U,$J,358.3,421,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,421,1,3,0)
 ;;=3^Hb-SS disease with acute chest syndrome
 ;;^UTILITY(U,$J,358.3,421,1,4,0)
 ;;=4^D57.01
 ;;^UTILITY(U,$J,358.3,421,2)
 ;;=^5002307
 ;;^UTILITY(U,$J,358.3,422,0)
 ;;=D57.00^^2^20^5
 ;;^UTILITY(U,$J,358.3,422,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,422,1,3,0)
 ;;=3^Hb-SS disease with crisis, unspecified
 ;;^UTILITY(U,$J,358.3,422,1,4,0)
 ;;=4^D57.00
 ;;^UTILITY(U,$J,358.3,422,2)
 ;;=^5002306
 ;;^UTILITY(U,$J,358.3,423,0)
 ;;=D57.20^^2^20^17
 ;;^UTILITY(U,$J,358.3,423,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,423,1,3,0)
 ;;=3^Sickle-cell/Hb-C disease without crisis
 ;;^UTILITY(U,$J,358.3,423,1,4,0)
 ;;=4^D57.20
 ;;^UTILITY(U,$J,358.3,423,2)
 ;;=^330080
 ;;^UTILITY(U,$J,358.3,424,0)
 ;;=D57.811^^2^20^10
 ;;^UTILITY(U,$J,358.3,424,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,424,1,3,0)
 ;;=3^Sickle-Cell Disorders w/ Acute Chest Syndrome NEC
 ;;^UTILITY(U,$J,358.3,424,1,4,0)
 ;;=4^D57.811
 ;;^UTILITY(U,$J,358.3,424,2)
 ;;=^5002318
 ;;^UTILITY(U,$J,358.3,425,0)
 ;;=D57.812^^2^20^11
 ;;^UTILITY(U,$J,358.3,425,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,425,1,3,0)
 ;;=3^Sickle-Cell Disorders w/ Splenic Sequestration
 ;;^UTILITY(U,$J,358.3,425,1,4,0)
 ;;=4^D57.812
 ;;^UTILITY(U,$J,358.3,425,2)
 ;;=^5002319
 ;;^UTILITY(U,$J,358.3,426,0)
 ;;=D57.819^^2^20^12
 ;;^UTILITY(U,$J,358.3,426,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,426,1,3,0)
 ;;=3^Sickle-Cell Disorders w/ Unspec Crisis NEC
 ;;^UTILITY(U,$J,358.3,426,1,4,0)
 ;;=4^D57.819
 ;;^UTILITY(U,$J,358.3,426,2)
 ;;=^5002320
 ;;^UTILITY(U,$J,358.3,427,0)
 ;;=D58.8^^2^20^9
 ;;^UTILITY(U,$J,358.3,427,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,427,1,3,0)
 ;;=3^Hereditary Hemolytic Anemias NEC
 ;;^UTILITY(U,$J,358.3,427,1,4,0)
 ;;=4^D58.8
 ;;^UTILITY(U,$J,358.3,427,2)
 ;;=^267984
 ;;^UTILITY(U,$J,358.3,428,0)
 ;;=D58.2^^2^20^8
 ;;^UTILITY(U,$J,358.3,428,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,428,1,3,0)
 ;;=3^Hemoglobinopathies NEC
 ;;
 ;;$END ROU IBDEI022
